RegulomeX
AI Genomics Engine for Disease Treatment
Company Overview
Snapshot
Founded in April 2024 by Alex Ackerman, RegulomeX operates with 1–10 employees. The company ceased to operate in September 2024.
Business overview
RegulomeX is a biotechnology startup that utilizes advanced artificial intelligence to analyze the non-coding regions of the human genome. Its core technology, the Regulatory Genome Language Model, employs generative AI to identify regulatory elements controlling gene expression, providing insights into genetic mechanisms for complex diseases. The company aims to advance personalized medicine and drug discovery by developing targeted therapies based on individual genetic profiles, serving the healthcare and life sciences markets, specifically within the biotechnology and pharmaceuticals sectors.
Log in to access full profile ›Company Intelligence Q&A
- When was RegulomeX founded?
- RegulomeX was founded in April 2024.
- Who is the founder of RegulomeX?
- Alex Ackerman is the co-founder and CEO of RegulomeX.
- What is RegulomeX's primary focus?
- RegulomeX focuses on leveraging artificial intelligence to decode non-coding regions of the human genome to understand genetic mechanisms underlying complex diseases and develop targeted therapies.
- What is the status of RegulomeX?
- RegulomeX ceased to operate in September 2024.
- What technology does RegulomeX use?
- RegulomeX utilizes its proprietary Regulatory Genome Language Model, which harnesses generative AI to uncover regulatory elements that control gene expression.